The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
Open accessAbstract
Background The phase 3 LUME-Lung 1 study assessed the efficacy and safety of docetaxel plus nintedanib as second-line therapy for non-small-cell lung cancer (NSCLC).Methods Patients from 211 centres in 27 countries with stage IIIB/IV recurrent NSCLC progressing after first-line chemotherapy, stratified by ECOG performance status, previous bevacizumab treatment, histology, and presence of brain metastases, were allocated (by computer-generated sequence through an interactive third-party system, in 1:1 ratio), to receive docetaxel 75 mg/m(2) by intravenous infusion on day 1 plus either nintedanib 200 mg orally twice daily or matching placebo on days 2-21, every 3 weeks until unacceptable adverse events or disease progression. Investigators and patients were masked to assignment. The primary endpoint was progression-free survival (PFS) by independent central review, analysed by intention to treat after 714 events in all patients. The key secondary endpoint was overall survival, analysed by intention to treat after 1121 events had occurred, in a prespecified stepwise order: first in patients with adenocarcinoma who progressed within 9 months after start of first-line therapy, then in all patients with adenocarcinoma, then in all patients. This trial is registered with ClinicalTrials.gov, number NCT00805194.Findings Between Dec 23, 2008, and Feb 9, 2011, 655 patients were randomly assigned to receive docetaxel plus nintedanib and 659 to receive docetaxel plus placebo. The primary analysis was done after a median follow-up of 7·1 months (IQR 3·8-11·0). PFS was significantly improved in the docetaxel plus nintedanib group compared with the docetaxel plus placebo group (median 3·4 months [95% CI 2·9-3·9] vs 2·7 months [2·6-2·8]; hazard ratio [HR] 0·79 [95% CI 0·68-0·92], p=0·0019). After a median follow-up of 31·7 months (IQR 27·8-36·1), overall survival was significantly improved for patients with adenocarcinoma histology who progressed within 9 months after start of first-line treatment in the docetaxel plus nintedanib group (206 patients) compared with those in the docetaxel plus placebo group (199 patients; median 10·9 months [95% CI 8·5-12·6] vs 7·9 months [6·7-9·1]; HR 0·75 [95% CI 0·60-0·92], p=0·0073). Similar results were noted for all patients with adenocarcinoma histology (322 patients in the docetaxel plus nintedanib group and 336 in the docetaxel plus placebo group; median overall survival 12·6 months [95% CI 10·6-15·1] vs 10·3 months [95% CI 8·6-12·2]; HR 0·83 [95% CI 0·70-0·99], p=0·0359), but not in the total study population (median 10·1 months [95% CI 8·8-11·2] vs 9·1 months [8·4-10·4]; HR 0·94, 95% CI 0·83-1·05, p=0·2720). Grade 3 or worse adverse events that were more common in the docetaxel plus nintedanib group than in the docetaxel plus placebo group were diarrhoea (43 [6·6%] of 652 vs 17 [2·6%] of 655), reversible increases in alanine aminotransferase (51 [7·8%] vs six [0·9%]), and reversible increases in aspartate aminotransferase (22 [3·4%] vs three [0·5%]). 35 patients in the docetaxel plus nintedanib group and 25 in the docetaxel plus placebo group died of adverse events possibly unrelated to disease progression; the most common of these events were sepsis (five with docetaxel plus nintedanib vs one with docetaxel plus placebo), pneumonia (two vs seven), respiratory failure (four vs none), and pulmonary embolism (none vs three).Interpretation Nintedanib in combination with docetaxel is an effective second-line option for patients with advanced NSCLC previously treated with one line of platinum-based therapy, especially for patients with adenocarcinoma.Funding Boehringer Ingelheim.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Compared with docetaxel, the combination of nintedanib and docetaxel was associated with a higher incidence of gastrointestinal AEs and transient elevation of liver enzymes [102].”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [102]
In the citing paper
“Additional unplanned analyses revealed a pronounced impact on OS in patients with fast-progressing disease and patients who were refractory to first-line chemotherapy.”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [102]
In the citing paper
“Unfortunately, survival outcomes remain poor and patients often experience substantial toxicity, underscoring a high unmet need. 8 , 9”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C. D., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,468
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Comprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
A note on quantifying follow-up in studies of failure time
SCHEMPER, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,592
Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Shepherd, F. A., Dancey, J. E., Ramlau, R., Mattson, K. V., Gralla, R. J., O’Rourke, M. A., Levitan, N. I., Gressot, L., Vincent, M. D., Burkes, R. L., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.10.2095 · Cited by 2,178
Research works printed but not linked: 2
- Hanna, 2013, Retrospective evaluation of the futility analysis in LUME-Lung 2, a randomised, double-blind, placebo-controlled phase III trial of nintedanib (BIBF 1120) in combination with pemetrexed in NSCLC patients progressing after one prior first-line chemotherapy, Eur J Cancer, 49, 3418
- Reck, 2013, Impact of tumor burden on the overall survival analysis of the LUME-Lung 1 study: a randomized, double-blind phase 3 trial of nintedanib (BIBF 1120) + docetaxel in NSCLC patients progressing after first-line chemotherapy, J Thorac Oncol, 8, O16.01
Cited by
Sorted by citations
Items 101–200 of 952
Molecular Mechanisms and Cellular Contribution from Lung Fibrosis to Lung Cancer Development
Samarelli, A. V., Masciale, V., Aramini, B., Coló, G. P., Tonelli, R., Marchioni, A., Bruzzi, G., Gozzi, F., Andrisani, D., Castaniere, I., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212179 · Cited by 94
The Role of TGF-β Signaling in Lung Cancer Associated with Idiopathic Pulmonary Fibrosis
Saito, A., Horie, M., Micke, P., & Nagase, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113611 · Cited by 94
Hanna, N. H., Kaiser, R., Sullivan, R. N., Aren, O. R., Ahn, M., Tiangco, B., Voccia, I., von Pawel, J., Kovčin, V., Agulnik, J. S., et al. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.10.011 · Cited by 88
Self-citationComorbid Conditions in Idiopathic Pulmonary Fibrosis: Recognition and Management
Oldham, J. M., & Collard, H. R. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00123 · Cited by 94
Recent advances in anti-angiogenic nanomedicines for cancer therapy
Bhattarai, P., Hameed, S., & Dai, Z. (2018) · Nanoscale · doi:10.1039/c7nr09612g · Cited by 90
Treatment of advanced squamous cell carcinoma of the lung: a review.
Derman, B. A., Mileham, K. F., Bonomi, P., Batus, M., & Fidler, M. J. (2015) · PubMed · doi:10.3978/j.issn.2218-6751.2015.06.07 · Cited by 90
Otsubo, K., Kishimoto, J., Ando, M., Kenmotsu, H., Minegishi, Y., Horinouchi, H., Kato, T., Ichihara, E., Kondo, M., Atagi, S., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.00380-2022 · Cited by 89
Deben, C., Deschoolmeester, V., Lardon, F., Rolfo, C. D., & Pauwels, P. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.11.019 · Cited by 86
Garassino, M. C., Gelibter, A. J., Grossi, F., Chiari, R., Parra, H. J. S., Cascinu, S., Cognetti, F., Turci, D., Blasi, L., Bengala, C., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.04.025 · Cited by 85
Idiopathic pulmonary fibrosis and lung cancer
Antoniou, K. M., Tomassetti, S., Tsitoura, E., & Vancheri, C. (2015) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000217 · Cited by 85
Cao, Z., Quazi, S., Arora, S., Osellame, L. D., Burvenich, I. J. G., Janes, P. W., & Scott, A. M. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-024-01099-2 · Cited by 94
Synthetically lethal nanoparticles for treatment of endometrial cancer
Ebeid, K., Meng, X., Thiel, K. W., Do, A., Geary, S. M., Morris, A. S., Pham, E. L., Wongrakpanich, A., Chhonker, Y. S., Murry, D. J., et al. (2017) · Nature Nanotechnology · doi:10.1038/s41565-017-0009-7 · Cited by 82
Rulli, E., Ghilotti, F., Biagioli, E. C., Porcu, L., Marabese, M., D’Incalci, M., Bellocco, R., & Torri, V. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0302-8 · Cited by 86
Impact of idiopathic pulmonary fibrosis on advanced non-small cell lung cancer survival
Kanaji, N., Tadokoro, A., Kita, N., Murota, M., Ishii, T., Takagi, T., Watanabe, N., Tojo, Y., Harada, S., Hasui, Y., et al. (2016) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-016-2199-z · Cited by 84
Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC)
Yoneda, K., Imanishi, N., Ichiki, Y., & Tanaka, F. (2018) · Journal of UOEH · doi:10.7888/juoeh.40.173 · Cited by 80
Regulatory Immune Cells in Idiopathic Pulmonary Fibrosis: Friends or Foes?
van Geffen, C., Deißler, A., Quante, M., Renz, H. E., Hartl, D., & Kolahian, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.663203 · Cited by 82
Besse, B., Felip, E., Campelo, R. G., Cobo, M., Mascaux, C., Madroszyk, A., Cappuzzo, F., Hilgers, W., Romano, G. D., Denis, F., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.07.006 · Cited by 83
Self-citationmiR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells
Nishijima, N., Seike, M., Soeno, C., Chiba, M., Miyanaga, A., Noro, R., Sugano, T., Matsumoto, M., Kubota, K., & Gemma, A. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3331 · Cited by 82
Miura, Y., Saito, T., Tanaka, T., Takoi, H., Yatagai, Y., Inomata, M., Nei, T., Saito, Y., Gemma, A., & Azuma, A. (2017) · Respiratory Investigation · doi:10.1016/j.resinv.2017.09.007 · Cited by 80
Remón, J., Besse, B., & Soria, J. (2017) · BMC Medicine · doi:10.1186/s12916-017-0819-3 · Cited by 81
Gregorc, V., Gaafar, R. M., Favaretto, A. G., Grossi, F., Jassem, J., Polychronis, A., Bidoli, P., Tiseo, M., Shah, R. N. H., Taylor, P., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30193-1 · Cited by 79
Self-citationParker, A. L., Bowman, E. D., Zingone, A., Ryan, B. M., Cooper, W. A., Kohonen‐Corish, M. R. J., Harris, C. C., & Cox, T. R. (2022) · Genome Medicine · doi:10.1186/s13073-022-01127-6 · Cited by 78
Targeting Angiogenesis in Colorectal Carcinoma
Lopez, A., Harada, K., Vassilakopoulou, M., Shanbhag, N. D., & Ajani, J. A. (2019) · Drugs · doi:10.1007/s40265-018-1037-9 · Cited by 80
Qiang, H., Chang, Q., Xu, J., Qian, J., Zhang, Y., Lei, Y., Han, B., & Chu, T. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03129-6 · Cited by 76
Malignant pleural mesothelioma: New hope in the horizon with novel therapeutic strategies
Remón, J., Reguart, N., Corral, J., & LIANES, P. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.10.007 · Cited by 74
Skinner, H. D., Giri, U. P., Yang, L. P., Woo, S. H., Story, M. D., Pickering, C. R., Byers, L. A., Williams, M. D., El‐Naggar, A. K., Wang, J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2785 · Cited by 76
Saif, M. W., Knost, J. A., Chiorean, E. G., Kambhampati, S. R. P., Yu, D., Pytowski, B., Qin, A., Kauh, J. S. W., & O’Neil, B. H. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3134-3 · Cited by 74
Cortot, A. B., Audigier-Valette, C., Molinier, O., Moulec, S. L., Barlési, F., Zalcman, G., Dumont, P., Pouessel, D., Poulet, C., Fontaine-Delaruelle, C., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.02.022 · Cited by 72
Shukuya, T., Mori, K. P., Amann, J. M., Bertino, E. M., Otterson, G. A., Shields, P. G., Morita, S., & Carbone, D. P. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.07.017 · Cited by 74
Cardiovascular Complications of Systemic Therapy in Non-Small-Cell Lung Cancer
Zaborowska-Szmit, M., Krzakowski, M. J., Kowalski, D. M., & Szmit, S. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051268 · Cited by 73
Self-citationKato, R., Haratani, K., Hayashi, H., Sakai, K., Sakai, H., Kawakami, H., Tanaka, K., Takeda, M., Yonesaka, K., Nishio, K., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01201-z · Cited by 71
Karampitsakos, Τ., Spagnolo, P., Moğulkoç, N., Wuyts, W. A., Tomassetti, S., Bendstrup, E. M., Molina‐Molina, M., Manali, E. D., Unat, Ö. S., Bonella, F., et al. (2022) · Respirology · doi:10.1111/resp.14363 · Cited by 68
Profile of nintedanib in the treatment of solid tumors: the evidence to date
Awasthi, N., & Schwarz, R. E. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s78805 · Cited by 68
Immunotherapy in non-small cell lung cancer: update and new insights
Mielgo-Rubio, X., Uribelarrea, E. A., Cortés, L. Q., & Moyano, M. S. (2021) · Journal of Clinical and Translational Research · doi:10.18053/jctres.07.202101.001 · Cited by 65
Novello, S., Kaiser, R., Mellemgaard, A., Douillard, J.-Y., Orlov, S., Krzakowski, M., von Pawel, J., Gottfried, M., Bondarenko, I., Liao, M., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2014.11.015 · Cited by 66
Self-citationStrategies targeting angiogenesis in advanced non-small cell lung cancer
Wang, J., Chen, J., Guo, Y., Wang, B., & Chu, H. (2017) · Oncotarget · doi:10.18632/oncotarget.17957 · Cited by 64
Toyoda, T., Kamata, T., Tanaka, K., Ihara, F., Takami, M., Suzuki, H., Nakajima, T., Ikeuchi, T., Kawasaki, Y., Hanaoka, H., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000316 · Cited by 68
FGFR as potential target in the treatment of squamous non small cell lung cancer
Tiseo, M., Gelsomino, F., Alfieri, R. R., Cavazzoni, A., Bozzetti, C., Giorgi, A. D., Petronini, P. G., & Ardizzoni, A. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.04.011 · Cited by 67
Optimizing lung cancer treatment approaches
Rosell, R., & Karachaliou, N. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.225 · Cited by 66
Reis, R., Labat, L., Allard, M., Boudou, P., Chapron, J., Bellesœur, A., Thomas‐Schoemann, A., Arrondeau, J., Giraud, F., Alexandre, J., et al. (2018) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2018.05.052 · Cited by 64
The Role of Anti-angiogenesis in Non-small-cell Lung Cancer: an Update
Villaruz, L. C., & Socinski, M. A. (2015) · Current Oncology Reports · doi:10.1007/s11912-015-0448-y · Cited by 64
Hong, S., Tan, M. H., Wang, S., Luo, S., Chen, Y., & Zhang, L. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1862-5 · Cited by 63
Domen, A., Quatannens, D., Zanivan, S. R., Deben, C., Audenaerde, J. R. M. V., Smits, E., Wouters, A., Lardon, F., Roeyen, G., Verhoeven, Y., et al. (2021) · Cancers · doi:10.3390/cancers13050987 · Cited by 64
Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer
Awasthi, N., Hinz, S., Brekken, R. A., Schwarz, M. A., & Schwarz, R. E. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.12.027 · Cited by 63
Krchniakova, M., Skoda, J., Neradil, J., Chlapek, P., & Veselska, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093157 · Cited by 61
Interleukin-1 (IL-1) and the inflammasome in cancer
Prêtre, V., Papadopoulos, D., Regard, J. B., Pelletier, M. R., & Woo, J. (2022) · Cytokine · doi:10.1016/j.cyto.2022.155850 · Cited by 66
Lysosomes as a Target of Anticancer Therapy
Trybus, W., Trybus, E., & Król, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032176 · Cited by 65
SPP1 induces idiopathic pulmonary fibrosis and NSCLC progression via the PI3K/Akt/mTOR pathway
Yue, B., Xiong, D., Chen, J., Yang, X., Zhao, J., Shao, J., Wei, D., Gao, F., Huang, M., & Chen, J. (2024) · Respiratory Research · doi:10.1186/s12931-024-02989-7 · Cited by 61
Zhao, S., Cheng, Y., Wang, Q. J., Li, X., Liao, J., Rodon, J. A., Meng, X., Luo, Y., Chen, Z., Wang, W., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03638-2 · Cited by 67
Bevacizumab in advanced lung cancer: state of the art
Assoun, S., Brosseau, S., Steinmetz, C., Gounant, V., & Zalcman, G. (2017) · Future Oncology · doi:10.2217/fon-2017-0302 · Cited by 63
Gabasa, M., Ikemori, R., Hilberg, F., Reguart, N., & Alcaraz, J. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.270 · Cited by 61
Norden, A. D., Schiff, D., Ahluwalia, M. S., Lesser, G. J., Nayak, L., Lee, E. Q., Rinne, M. L., Muzikansky, A., Dietrich, J., Purow, B. W., et al. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1631-y · Cited by 60
Daum, S., Hagen, H., Naismith, E., Wolf, D. G. F., & Pircher, A. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.610903 · Cited by 60
Immunotherapy in Lung Cancer: A New Age in Cancer Treatment
Corrales, L., Scilla, K. A., Caglevic, C., Miller, K., Oliveira, J., & Rolfo, C. D. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-02505-2_3 · Cited by 65
Matrix Stiffening and β1 Integrin Drive Subtype-Specific Fibroblast Accumulation in Lung Cancer
Puig, M., Lugo, R., Gabasa, M., Garcia-Gimenez, A., Velásquez, A., Galgoczy, R., Ramírez, J., Gómez-Caro, A. A., Busnadiego, Ó., Rodríguez‐Pascual, F., et al. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0155 · Cited by 59
Anti-angiogenic Therapy for Retinal Disease
Paulus, Y. M., & Sodhi, A. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_78 · Cited by 60
Roles of Mir-200 Family Members in Lung Cancer: More Than Tumor Suppressors
Liu, C., Hu, W., Li, L.-L., Wang, Y., Zhou, Q. Y., Zhang, F., Songyang, Y., Zhu, W., Sun, C., & Li, D. (2018) · Future Oncology · doi:10.2217/fon-2018-0155 · Cited by 59
Low, J. L., Walsh, R. J., Ang, Y. L. E., Chan, G. H. J., & Soo, R. A. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919870360 · Cited by 59
Saka, H., Kitagawa, C., Kogure, Y., Takahashi, Y., Fujikawa, K., Sagawa, T., Iwasa, S., Takahashi, N., Fukao, T., Tchinou, C., et al. (2017) · Investigational New Drugs · doi:10.1007/s10637-016-0416-x · Cited by 57
Nintedanib induces senolytic effect via STAT3 inhibition
Cho, H.-J., Hwang, J.-A., Yang, E. J., Kim, E.-C., Kim, J., Kim, S. Y., Kim, Y. Z., Park, S. C., & Lee, Y. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05207-8 · Cited by 57
Garde, J., Martín-Martorell, P., Julián, M. D., Altozano, J. P., Coloma, C. S., García-Sánchez, J., Insa, A., Martín, M., Mielgo-Rubio, X., Marín-Liébana, S., et al. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-017-1829-5 · Cited by 56
SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015
García‐Campelo, R., Bernabé, R., Cobo, M., Corral, J., Coves, J., Dómine, M., Nadal, E., Rodríguez‐Abreu, D., Viñolas, N., & Massutí, B. (2015) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1455-z · Cited by 55
Antiangiogenic Therapies in Non-Small-Cell Lung Cancer
Alshangiti, A., Chandhoke, G., & Ellis, P. M. (2018) · Current Oncology · doi:10.3747/co.25.3747 · Cited by 54
Bonanno, L., De Paoli, A., Zulato, E., Esposito, G., Calabrese, F., Favaretto, A., Santo, A., Conte, A. D., Chilosi, M., Oniga, F., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2410 · Cited by 53
The microtubule cytoskeleton: An old validated target for novel therapeutic drugs
Lafanéchère, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.969183 · Cited by 53
Mackintosh, J. A., Keir, G. J., Troy, L. K., Holland, A. E., Grainge, C., Chambers, D. C., Sandford, D., Jo, H. E., Glaspole, I., WILSHER, M. L., et al. (2024) · Respirology · doi:10.1111/resp.14656 · Cited by 54
Ramucirumab: preclinical research and clinical development
Aprile, G., Fontanella, C., Rihawi, K., Grossi, F., & Rijavec, E. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s61132 · Cited by 53
Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer
Jiang, W., & Ji, M. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.03.006 · Cited by 55
Systemic Sclerosis Association with Malignancy
Lepri, G., Catalano, M., Bellando-Randone, S., Pillozzi, S., Giommoni, E., Giorgione, R., Botteri, C., Matucci‐Cerinic, M., Antonuzzo, L., & Guiducci, S. (2022) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-022-08930-4 · Cited by 53
Shintani, Y., Kimura, T., Funaki, S., Ose, N., Kanou, T., & Fukui, E. (2023) · Cancers · doi:10.3390/cancers15020335 · Cited by 54
Treatment of NSCLC after chemoimmunotherapy — are we making headway?
Reck, M., Frost, N., Peters, S., Fox, B. A., Ferrara, R., Savai, R., & Barlési, F. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01061-7 · Cited by 62
Self-citationPharmacokinetic Properties of Nintedanib in Healthy Volunteers and Patients With Advanced Cancer
Dallinger, C., Trommeshauser, D., Marzin, K., Liesener, A., Kaiser, R., & Stopfer, P. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.752 · Cited by 52
Self-citationDeciphering role of FGFR signalling pathway in pancreatic cancer
Kang, X., Zeng, L., Xu, M., Pan, J., & Wang, Z. P. (2019) · Cell Proliferation · doi:10.1111/cpr.12605 · Cited by 52
Liang, H., & Wang, M. (2019) · Cancer Management and Research · doi:10.2147/cmar.s212238 · Cited by 54
Targeting cancer-associated fibroblasts: Challenges, opportunities and future directions
Jenkins, B. H., Buckingham, J. F., Hanley, C. J., & Thomas, G. J. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108231 · Cited by 56
Alcaraz, J., Carrasco, J. L., Millares, L., Luis, I.-C., Fernández-Porras, F. J., Martínez-Romero, A., Díaz‐Valdivia, N., de Cos, J. S., Rami–Porta, R., Seijo, L. M., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.07.020 · Cited by 51
Τzouvelekis, Α., Karampitsakos, Τ., Gomatou, G., Bouros, E., Tzilas, V., Manali, E., Tomos, I. P., Trachalaki, A., Kolilekas, L., Korbila, I. P., et al. (2019) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2019.101880 · Cited by 51
Angiogenesis in NSCLC: is vessel co-option the trunk that sustains the branches?
Coelho, A., Gomes, M. P., Catarino, R., Rolfo, C. D., Lopes, A. M., Medeiros, R., & Araújo, A. (2016) · Oncotarget · doi:10.18632/oncotarget.7794 · Cited by 50
Cheng, K., Liu, C., & Rao, G. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200514082425 · Cited by 52
Clinical advances and challenges in targeting FGF/FGFR signaling in lung cancer
Peng, M., Deng, J., & Li, X. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02167-9 · Cited by 49
Bronte, G., Bronte, E., Novo, G., Pernice, G., Vullo, F. L., Musso, E., Bronte, F., Gulotta, E., Rizzo, S., Rolfo, C. D., et al. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.986092 · Cited by 49
Biological therapies in nonsmall cell lung cancer
Zugazagoitia, J., Molina‐Pinelo, S., López‐Ríos, F., & Paz-Ares, L. G. (2017) · European Respiratory Journal · doi:10.1183/13993003.01520-2016 · Cited by 49
Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer
Hardin, C., Shum, E., Ap, S., Perez-Soler, R., & Cheng, H. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1316374 · Cited by 49
Circulating tumor DNA in blood: Future genomic biomarkers for cancer detection
Sumbal, S., Javed, A., Afroze, B., Zulfiqar, H. F., Javed, F., Noreen, S., & Ijaz, B. (2018) · Experimental Hematology · doi:10.1016/j.exphem.2018.06.003 · Cited by 48
Reguera-Nuñez, E., Xu, P., Chow, A., Man, S., Hilberg, F., & Kerbel, R. S. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0999-5 · Cited by 51
Kurzrock, R., & Stewart, D. J. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1968 · Cited by 49
Personalised medicine for nonsmall cell lung cancer
Mascaux, C., Tomasini, P., Greillier, L., & Barlési, F. (2017) · European Respiratory Review · doi:10.1183/16000617.0066-2017 · Cited by 49
Passiglia, F., Pilotto, S., Facchinetti, F., Bertolaccini, L., Re, M. D., Ferrara, R., Franchina, T., Malapelle, U., Menis, J., Passaro, A., et al. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.102858 · Cited by 48
Self-citationOtsubo, K., Kishimoto, J., Kenmotsu, H., Minegishi, Y., Ichihara, E., Shiraki, A., Kato, T., Atagi, S., Horinouchi, H., Ando, M., et al. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.06.003 · Cited by 46
Ruysscher, D. D., Granton, P. V., Lieuwes, N. G., van Hoof, S. J., Wollin, L., Weynand, B., Dingemans, A. C., Verhaegen, F., & Dubois, L. J. (2017) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2017.07.014 · Cited by 46
Reck, M., Paz-Ares, L. G., Bidoli, P., Cappuzzo, F., Dakhil, S. R., Moro‐Sibilot, D., Borghaei, H., Johnson, M. L., Jotte, R. M., Pennell, N. A., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.07.038 · Cited by 46
Self-citationEnzymes involved in tumor-driven angiogenesis: A valuable target for anticancer therapy
Ricciuti, B., Foglietta, J., Bianconi, V., Sahebkar, A., & Pirro, M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.005 · Cited by 45
Anti-Angiogenic Therapy in the Treatment of Non-Small Cell Lung Cancer
Tian, W., Cao, C., Shu, L., & Wu, F. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s276150 · Cited by 46
Nivolumab: A Review in Advanced Nonsquamous Non-Small Cell Lung Cancer
Keating, G. M. (2016) · Drugs · doi:10.1007/s40265-016-0589-9 · Cited by 45
Theelen, W. S. M. E., Mittempergher, L., Willems, S. M., Bosma, A. J., Peters, D. D. G. C., van der Noort, V., Japenga, E. J., Peeters, T., Koole, K., Šuštić, T., et al. (2016) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.51 · Cited by 45
Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come
Toschi, L., Rossi, S., Finocchiaro, G., & Santoro, A. (2017) · ecancermedicalscience · doi:10.3332/ecancer.2017.787 · Cited by 48
Onesti, C. E., Frères, P., & Jérusalem, G. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.12.47 · Cited by 46
Zhu, Y., Liang, X., Lu, C., Kong, Y., Tang, X., Zhang, Y. X., Yin, T., Gou, J., Wang, Y., & He, H. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119569 · Cited by 45
A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors
de Braud, F., Cascinu, S., Spitaleri, G., Pilz, K., Clementi, L., Liu, D., Sikken, P., & Pas, T. M. D. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv354 · Cited by 45
Duch, P., Díaz‐Valdivia, N., Ikemori, R., Gabasa, M., Radisky, E. S., Arshakyan, M., Gea‐Sorlí, S., Mateu-Bosch, A., Bragado, P., Carrasco, J. L., et al. (2022) · Matrix Biology · doi:10.1016/j.matbio.2022.06.009 · Cited by 43
Metadata
- Authors
- Reck, M., Kaiser, R., Mellemgaard, A., Douillard, J.-Y., Orlov, S., Krzakowski, M., von Pawel, J., Gottfried, M., Bondarenko, I., Liao, M., Gann, C.-N., Barrueco, J., Gaschler-Markefski, B., & Novello, S.
- Affiliations
- German Center for Lung Research (DE)
- Boehringer Ingelheim (Germany) (DE)
- Herlev Hospital (DK)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
- Meir Medical Center (IL)
- Dnipro State Medical University (UA)
- Shanghai Jiao Tong University (CN)
- Boehringer Ingelheim (United States) (US)
- University of Turin (IT)
- ORCID
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2014-02
- Volume
- 15
- Issue
- 2
- Pages
- 143-155
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2170030318
- Cited by
- 951
- References
- 36
- Citations by year
- 2026: 35 · 2025: 41 · 2024: 64 · 2023: 67 · 2022: 74 · 2021: 67 · 2020: 72 · 2019: 83 · 2018: 81 · 2017: 117 · 2016: 103 · 2015: 102 · 2014: 45
- FWCI
- 98.24
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- non-small cell lung cancer, docetaxel, nintedanib, second-line therapy, progression-free survival, overall survival, tyrosine kinase inhibitors, EGFR inhibitors, bevacizumab, brain metastases, adenocarcinoma, targeted therapy, combination chemotherapy, drug safety and tolerability
- MeSH terms
- Docetaxel, Adenocarcinoma of Lung, Adenocarcinoma, Aged, Antineoplastic Combined Chemotherapy Protocols, Asia, Carcinoma, Non-Small-Cell Lung, Double-Blind Method, Europe, Female, Humans, Indoles, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Risk Factors, South Africa, Time Factors, Proportional Hazards Models, Odds Ratio, Treatment Outcome, Disease Progression, Disease-Free Survival, Taxoids, Protein Kinase Inhibitors, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
